REDWOOD CITY, Calif.,
June 11, 2015 /PRNewswire/
-- Genomic Health, Inc. (Nasdaq: GHDX) today announced that
results from a multi-center, proof-of-concept, bladder cancer
liquid biopsy study will be presented at the American Association
for Cancer Research (AACR) Precision Medicine Meeting in
Salt Lake City. The study was
co-led by Genomic Health, Vanderbilt
University Medical Center, Carolina Urologic Research
Center, Associated Medical Professionals of New York, and NorthShore University
HealthSystem, and conducted in collaboration with 10 additional
sites in the United States.
"The upcoming presentation is an important step for Genomic
Health's liquid biopsy program as we continue to develop
non-invasive cancer tests," said Ellen
Beasley, Ph.D., senior vice president, Research and
Development, Genomic Health.
The American Bladder Cancer Society estimates that over 72,000
men and women will be diagnosed with bladder cancer each year in
the United States. A man's chance
of getting bladder cancer in his lifetime is 1 in 26, while a
woman's is 1 in 90. Currently, bladder cancer surveillance is
performed via a cystoscopy – an invasive procedure that uses an
instrument equipped with a camera and light to look at the inside
of the bladder.
The poster, titled "Analysis of tumor DNA in urine as a highly
sensitive liquid biopsy for patients with non-muscle invasive
bladder cancer," will be presented on Monday, June 15, from 12-3
p.m. in the Grand Ballroom at the Grand America Hotel.
About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading
provider of genomic-based diagnostic tests that address both the
overtreatment and optimal treatment of early-stage cancer, one of
the greatest issues in healthcare today. The company is applying
its world-class scientific and commercial expertise and
infrastructure to lead the translation of massive amounts of
genomic data into clinically-actionable results for treatment
planning throughout the cancer patient's journey, from diagnosis to
treatment selection and monitoring. The company is based
in Redwood City, California, with European
headquarters in Geneva, Switzerland. For more
information, please visit, www.GenomicHealth.com and
follow the company on
Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the value and benefits of
urine-based monitoring of bladder cancer patients; the expectation
that the test results could enable a urine-based test for
monitoring bladder cancer recurrence in early-stage patients, and
the potential benefits of such a test; and the company's belief
that the study results demonstrate continued progress toward
development of non-invasive tests for individualized treatment at
various stages of disease. Forward-looking statements are subject
to risks and uncertainties that could cause actual results to
differ materially, and reported results should not be considered as
an indication of future performance. These risks and uncertainties
include, but are not limited to: the risks and uncertainties
associated with the regulation of the company's tests; the results
of clinical studies; the applicability of clinical study results to
actual outcomes; the company's ability to develop and commercialize
new tests, including tests based on liquid biopsy; the risk that
the company may not obtain or maintain sufficient levels of
reimbursement, domestically or abroad, for its existing tests and
any future tests it may develop; the risks of competition;
unanticipated costs or delays in research and development efforts;
and the other risks set forth in the company's filings with
the Securities and Exchange Commission, including the risks
set forth in the company's quarterly report on Form 10-Q for the
quarter ended March 31, 2015. These forward-looking statements
speak only as of the date hereof. Genomic
Health disclaims any obligation to update these
forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype
DX, Recurrence Score, and DCIS Score are trademarks or registered
trademarks of Genomic Health, Inc. All other trademarks
and service marks are the property of their respective
owners.
Logo -
http://photos.prnewswire.com/prnh/20130425/SF01493LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/genomic-health-to-present-proof-of-concept-bladder-cancer-liquid-biopsy-data-at-aacr-precision-medicine-meeting-300097538.html
SOURCE Genomic Health, Inc.